Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 592 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... August 7, 2023 What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... September 1, 2023 Empowering People With Cancer: A Q&A With Cancer.Net Editor in Chief... June 8, 2021 Load more HOT NEWS Selumetinib Continues to Show Promise in Children with NF1 To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... Worried Cancer Patients Face Delayed Treatment Because Of Pandemic High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast...
